Literature DB >> 12743325

In utero hematopoietic stem cell transplantation in nonhuman primates: the role of T cells.

Laurence E Shields1, Lakshmi K Gaur, Mike Gough, Jennifer Potter, Aimee Sieverkropp, Robert G Andrews.   

Abstract

In utero transplantation of hematopoietic stem cells is a promising treatment for immune and hematologic diseases of fetuses and newborns. Unfortunately, there are limited data from nonhuman primates and humans describing optimal transplantation conditions. The purpose of this investigation was to determine the effect of T-cell number on engraftment and the level of chimerism after in utero transplantation in nonhuman primates. CD34(+) allogeneic adult bone marrow cells, obtained from the sire after G-CSF and stem cell factor administration, were transplanted into female fetal recipients. The average CD34(+) cell dose was 3.0 x 10(9)/kg (range, 9.9 x 10(8) to 4.4 x 10(9)) and the T-cell dose ranged from 2.6 x 10(5) to 1.1 x 10(8)/kg. Chimerism was determined in peripheral blood subsets (CD2, CD13, and CD20) and in progenitor cell populations by using polymerase chain reaction. Chimerism was noted in seven of eight live-born animals. The level of chimerism in the progenitor population was related to the fetal T-cell dose (r = 0.64, p < 0.02). At the lowest T-cell dose (2.6 x 10(5)/kg), no chimerism was detected. As the T-cell dose increased to 10(6-7)/kg, the level of chimerism increased. Adjusting the T-cell dose to 1.1 x 10(8)/kg resulted in fatal graft-versus-host disease (GVHD). The results of this study emphasize the importance of T cells in facilitating donor cell engraftment and in producing GVHD in fetal nonhuman primates. Some animals achieved levels of chimerism in the marrow hematopoietic progenitor cell population that would likely have clinical relevance. However, the levels of chimerism in peripheral blood were too low for therapeutic benefit. Further studies are needed to test methods that are likely to enhance donor cell engraftment and peripheral blood levels of donor cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12743325     DOI: 10.1634/stemcells.21-3-304

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  13 in total

1.  CD26 inhibition enhances allogeneic donor-cell homing and engraftment after in utero hematopoietic-cell transplantation.

Authors:  William H Peranteau; Masayuki Endo; Obinna O Adibe; Aziz Merchant; Philip W Zoltick; Alan W Flake
Journal:  Blood       Date:  2006-09-05       Impact factor: 22.113

2.  Source of cell injected is a critical factors for short and long engraftment in xeno-transplantation.

Authors:  G Noia; M S Ligato; E Cesari; D Visconti; G Fortunato; M Tintoni; I Mappa; C Greco; M E Caristo; G Bonanno; M Corallo; L Minafra; A Perillo; M Terzano; S Rutella; G Leone; G Scambia; M Michejda; S Mancuso
Journal:  Cell Prolif       Date:  2008-02       Impact factor: 6.831

3.  Prenatal transplantation of cytokine-stimulated marrow improves early chimerism in a resistant strain combination but results in poor long-term engraftment.

Authors:  Aimen F Shaaban; Heung Bae Kim; Lasya Gaur; Kenneth W Liechty; Alan W Flake
Journal:  Exp Hematol       Date:  2006-09       Impact factor: 3.084

4.  Early chimerism threshold predicts sustained engraftment and NK-cell tolerance in prenatal allogeneic chimeras.

Authors:  Emily T Durkin; Kelly A Jones; Deepika Rajesh; Aimen F Shaaban
Journal:  Blood       Date:  2008-09-16       Impact factor: 22.113

5.  Haploidentical in utero hematopoietic cell transplantation improves phenotype and can induce tolerance for postnatal same-donor transplants in the canine leukocyte adhesion deficiency model.

Authors:  William H Peranteau; Todd E Heaton; Yu-Chen Gu; Susan W Volk; Thomas R Bauer; Keith Alcorn; Laura M Tuschong; Mark P Johnson; Dennis D Hickstein; Alan W Flake
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

Review 6.  Immunological considerations in in utero hematopoetic stem cell transplantation (IUHCT).

Authors:  Andrea I Loewendorf; Marie Csete; Alan Flake
Journal:  Front Pharmacol       Date:  2015-01-06       Impact factor: 5.810

Review 7.  NK cell tolerance as the final endorsement of prenatal tolerance after in utero hematopoietic cellular transplantation.

Authors:  Amir M Alhajjat; Amanda E Lee; Beverly S Strong; Aimen F Shaaban
Journal:  Front Pharmacol       Date:  2015-03-18       Impact factor: 5.810

Review 8.  In Utero Stem Cell Transplantation: Potential Therapeutic Application for Muscle Diseases.

Authors:  Neeladri Chowdhury; Atsushi Asakura
Journal:  Stem Cells Int       Date:  2017-05-15       Impact factor: 5.443

Review 9.  In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application.

Authors:  Graça Almeida-Porada; Anthony Atala; Christopher D Porada
Journal:  Mol Ther Methods Clin Dev       Date:  2016-03-30       Impact factor: 6.698

Review 10.  Transplant Tolerance Induction in Newborn Infants: Mechanisms, Advantages, and Potential Strategies.

Authors:  Hua Pan; Aram Gazarian; Jean-Michel Dubernard; Alexandre Belot; Marie-Cécile Michallet; Mauricette Michallet
Journal:  Front Immunol       Date:  2016-04-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.